JAK2V617F status of HPCs assayed from PMF CD34+ cells treated with SAHA alone
| . | PB granulocytes . | Source of hematopoietic colonies assayed . | |||||
|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ cells treated with cytokines + SAHA alone . | |||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 2 | 60* | 90 (27/30)† | 80 (24/30) | 100 (34/34) | 62 (21/34) | 100 (35/35) | 54 (19/35) |
| Patient 6 | 77 | 97 (29/30) | 93 (28/30) | 88 (7/17) | 41 (15/17) | 96 (21/22) | 82 (18/22) |
| . | PB granulocytes . | Source of hematopoietic colonies assayed . | |||||
|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ cells treated with cytokines + SAHA alone . | |||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 2 | 60* | 90 (27/30)† | 80 (24/30) | 100 (34/34) | 62 (21/34) | 100 (35/35) | 54 (19/35) |
| Patient 6 | 77 | 97 (29/30) | 93 (28/30) | 88 (7/17) | 41 (15/17) | 96 (21/22) | 82 (18/22) |
Indicates the percentage of JAK2V617F allele obtained from granulocytes by real-time quantitative kinetic PCR assay using allelic discrimination method.
Each value represents the percentage of colonies (CFU-GM + BFU-E + CFU-Mixed) exhibiting the JAK2V617F mutation or homozygous JAK2V617F allele. The numbers in parentheses denote the actual number of JAK2V617F-positive or homozygous colonies/the total numbers of colonies (CFU-GM + BFU-E + CFU-Mixed) analyzed.